Cisplatin/radiation therapy cervical cancer

Results of Prospective Randomized Trials that Compared Neoadjuvant Cisplatin-Containing Chemotherapy Followed by Radiation Therapy with Radiation Therapy Alone in Patients with Locally Advanced Cervical Cancer (52)... 

Other potential radiation sensitizers for cervical cancer are being explored in phase I and II trials. Paclitaxel has been combined with cisplatin in several small phase I studies. Pignata et al. (29) found that 50 mg/m2 per week of paclitaxel could be combined with weekly cisplatin (30 mg/m2) and radiation therapy with acceptable toxicity, although 10 of 18 patients in their study had grade 3-4 hematologic toxicity. Chen etal. (30) also were able to give weekly paclitaxel at a dose of 50 mg/m2 (in this case combined with 50 mg/m2 of cisplatin every three weeks) with tolerable toxicity and minimal delay in planned radiation therapy. In both studies, the dose-limiting side effect appeared to be diarrhea. It should be noted that the total dose of cisplatin delivered in these trials was lower than that used in the most successful prospective trials of cisplatin or cisplatin and fluorouracil (Table 3). 

I.V. Chemotherapy Plus Radiation (Chemoradiation) In a multi-institutional study reported in 1999 by Morris et al. of MDACC, the effects of radiation therapy to the pelvic and paraaortic field were compared to that of pelvic irradiation and concurrent chemotherapy with 5FU and cisplatin in women with advanced cervical cancer. The estimated cumulative rates of survival at 5 years were 73% among patients treated with radiotherapy and chemotherapy and 58% among patients treated with radiotherapy alone. Because of the success of chemoradiation in the management... 

---